Novel Gene Therapy Shows Promise in Treating Chronic Pain

Chemogenetics is a process where molecules that control the excitation (stimulation) of neurons are engineered so they only become active in the presence of a non-toxic drug. This process has already shown promise as a means of suppressing such excitability in research involving animals. Jimena Perez-Sanchez, a postdoctoral research scientist at the Nuffield Department of Clinical Neurosciences and joint author of the study with Steven Middleton, and her colleagues have now shown that there is a chemogenetic approach that is suitable for human applications.

First, the team expressed the gene PSAM4-GlyR, a chemogenetic system based on the human protein receptors nicotinic acetylcholine and glycine, in mouse sensory neurons. They activated PSAM4-GlyR with the clinically approved drug varenicline, which inhibited sensory neurons and also reduced the pain hypersensitivity normally associated with arthritis or nerve injury in mice.

Then, the researchers went on to activate the PSAM4-GlyR system in sensory neurons derived from a patient with erythromelalgia, a condition characterised by burning pain. They found that this inhibited the neurons and normalised hyperactivity.

David Bennett, Professor of Neurology and Neurobiology and Jimena Perez-Sanchez, postdoctoral research scientist at the Nuffield Department of Clinical Neurosciences, commented: ‘The whole team are pleased to have shown the potential of a gene therapy approach for the treatment of chronic pain which remains one of the great unmet health needs. This has been achieved by switching off hyperactive nerve fibres. By targeting this initial component of the pain circuit we could avoid the addictive potential of existing pain killers such as opioids.’

Although further validation in human pain models is needed, the results demonstrate the contribution of sensory neuron hyperexcitability to persistent pain due to arthritis or injury to the nervous system. The researchers have shown the translational potential of engineering human protein receptors for the treatment of pain.

Reference: Perez-Sanchez J, Middleton SJ, Pattison LA, et al. A humanized chemogenetic system inhibits murine pain-related behavior and hyperactivity in human sensory neurons. Sci Transl Med. 2023;15(716):eadh3839. doi: 10.1126/scitranslmed.adh3839

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.